289 related articles for article (PubMed ID: 33087103)
1. Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies.
Wang B; Xu L; Li Q; Man S; Jin C; Liu L; Zhan S; Ning Y
BMC Cancer; 2020 Oct; 20(1):1021. PubMed ID: 33087103
[TBL] [Abstract][Full Text] [Related]
2. The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.
Li X; Gu G; Soliman F; Sanders AJ; Wang X; Liu C
Chemotherapy; 2018; 63(4):214-219. PubMed ID: 30347389
[TBL] [Abstract][Full Text] [Related]
3. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.
Honglian M; Zhouguang H; Fang P; Lujun Z; Dongming L; Yujin X; Yong B; Liming X; Yirui Z; Xiao H; Jin W; Yue K; Lvhua W; Ming C
Thorac Cancer; 2020 Apr; 11(4):898-906. PubMed ID: 32068962
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first-line chemotherapy in patients with advanced non-small cell lung cancer.
Cheng Y; Nie L; Liu Y; Jin Z; Wang X; Hu Z
Thorac Cancer; 2019 Jul; 10(7):1576-1580. PubMed ID: 31161695
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer.
Liu X; Guo Z; Su L; Zuo A; Gao M; Ji X; Lu J; Yang S; Jiang Y; Lu D
Invest New Drugs; 2024 Jun; 42(3):309-317. PubMed ID: 38700579
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer.
Rong B; Yang S; Li W; Zhang W; Ming Z
World J Surg Oncol; 2012 Aug; 10():170. PubMed ID: 22917490
[TBL] [Abstract][Full Text] [Related]
7. [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
Han BH; Xiu QY; Wang HM; Shen J; Gu AQ; Luo Y; Bai CX; Guo SL; Liu WC; Zhuang ZX; Zhang Y; Zhao YZ; Jiang LY; Shi CL; Jin B; Zhou JY; Jin XQ
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):854-9. PubMed ID: 22335953
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
Li N; Jin ZL; Liu ZJ; Wang J; Li K
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
[TBL] [Abstract][Full Text] [Related]
9. Endostar (rh-endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer: A meta-analysis.
An J; Lv W
Thorac Cancer; 2018 May; 9(5):606-612. PubMed ID: 29575575
[TBL] [Abstract][Full Text] [Related]
10. Endostar (rh-endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis.
Yuan M; Zhai Y; Men Y; Wang J; Deng L; Wang W; Bao Y; Yang X; Sun S; Ma Z; Liu Y; Wang J; Zhu H; Hui Z
Thorac Cancer; 2021 Dec; 12(23):3208-3215. PubMed ID: 34676669
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
Zhu J; Chen G; Niu K; Feng Y; Xie L; Qin S; Wang Z; Li J; Lang S; Zhuo W; Chen Z; Sun J
Future Oncol; 2022 Mar; 18(9):1077-1087. PubMed ID: 34986655
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
Han B; Xiu Q; Wang H; Shen J; Gu A; Luo Y; Bai C; Guo S; Liu W; Zhuang Z; Zhang Y; Zhao Y; Jiang L; Zhou J; Jin X
J Thorac Oncol; 2011 Jun; 6(6):1104-9. PubMed ID: 21532504
[TBL] [Abstract][Full Text] [Related]
13. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis.
Ge W; Cao DD; Wang HM; Jie FF; Zheng YF; Chen Y
Asian Pac J Cancer Prev; 2011; 12(11):2901-7. PubMed ID: 22393961
[TBL] [Abstract][Full Text] [Related]
14. Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis.
Biaoxue R; Xiguang C; Hua L; Wenlong G; Shuanying Y
BMC Cancer; 2016 Nov; 16(1):888. PubMed ID: 27842514
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of rh-endostatin combined with chemotherapy versus chemotherapy alone for advanced NSCLC: a meta-analysis review].
Cao D; Ge W; Wang H; Zhang L; Zheng Y; Zhang J
Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):404-13. PubMed ID: 21569645
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
[TBL] [Abstract][Full Text] [Related]
17. Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.
Wang Z; Zhang H; Zhou C; Long X; Guan R; Yang N; Zhang Y
Cancer Med; 2019 Apr; 8(4):1434-1441. PubMed ID: 30762300
[TBL] [Abstract][Full Text] [Related]
18. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis.
Ge W; Cao DD; Wang HM; Jie FF; Zheng YF; Chen Y
Asian Pac J Cancer Prev; 2011; 12(10):2705-11. PubMed ID: 22320978
[TBL] [Abstract][Full Text] [Related]
19. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
[TBL] [Abstract][Full Text] [Related]
20. Endostar improved efficacy of concurrent chemoradiotherapy with vinorelbine plus carboplatin in locally advanced lung squamous cell carcinoma patients with high serum Lp(a) concentration.
Xu H; Lv D; Meng Y; Wang M; Wang W; Zhou C; Zhou S; Chen X; Yang H
Ann Palliat Med; 2020 Mar; 9(2):298-307. PubMed ID: 32075401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
